Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

Company on Target to File Supplemental New Drug Application in the Fourth

Quarter

FRAZER, Pa., Aug. 16 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a 12-week, Phase 3 clinical trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in patients with breakthrough pain associated with a broad range of chronic non-cancer pain conditions. The study achieved statistical significance on the primary endpoint. Results across the 12 weeks of treatment showed both statistically significant and clinically relevant outcomes for patients with breakthrough pain who were already receiving and who were tolerant to opioid therapy for their underlying persistent pain. FENTORA is approved only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

"We are excited to complete our Phase 3 program with this third and final controlled study. These data show similar positive outcomes as those with FENTORA in treating breakthrough pain in opioid-tolerant patients with cancer, chronic neuropathic pain, and chronic low-back pain," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We plan to submit these data to the Food and Drug Administration in the fourth quarter as part of our supplemental New Drug Application."

About the Study

The double-blind, placebo-controlled, variable dose Phase 3 trial included 148 patients. The primary endpoint was the Sum of Pain Intensity Differences from five to 60 minutes (SPID(60)) as assessed after 12 weeks of treatment. SPID(60) is a measure that assesses analgesic efficacy of a pain medication over the first 60 minutes after treatment. Patients treated with FENTORA showed a statistically significant improvement on the primary endpoint (p<0.0001) compared with placebo. FENTORA was general
'/>"/>

SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 ... Almshouse Road, Warrington, Pa. , Details: The Hepatitis ... finding a cure for hepatitis B and improving the quality ... Crystal Ball on Friday, April 11 at Warrington Country Club ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Jordan , Caliper Life Sciences, ... Introduction , The ... Liquid Handler (ALH). This device is designed to permit individually and independently ... microplates for purposes of liquid transfer (tertiary dispensing). It can be configured ...
... Rudy Willebrords 1 and Bart Moyson ... 1 Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica ... 2 Caliper Life Sciences Benelux NV, Teralfene, Belgium ... The purpose of this paper is to report ...
... Lynn Jordan , ... Introduction , ... across multi-well plates and into individual columns (secondary dispensing) is of ... precision that can be achieved during a series of dispenses. Therefore, ...
Cached Biology Technology:Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 2Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 3Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 4Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 596 Well Pipetting Precision Testing Using the Sciclone ALH with a 384 Fixed-Cannula Array 296 Well Pipetting Precision Testing Using the Sciclone ALH with a 384 Fixed-Cannula Array 3Sciclone ALH Bulk Dispense Precision Testing 2
(Date:4/24/2014)... brain infection caused by fungus could now be treated in ... University of Liverpool scientists. , Cryptococcus a ... relatively neglected in medical research. They are found in ... East Asia and mainly affect people with weakened immune systems. ... The University research team has tested the effects of the ...
(Date:4/24/2014)... with new insights into the make-up of tropical forests, ... Basin have revealed unprecedented detail of the size, age ... satellite maps with hundreds of field plots. , ... the amount of carbon each tree can store. This ... which trees are given a cash value according to ...
(Date:4/24/2014)... droplet of clear liquid can bend light, acting as ... have developed a new process to create inexpensive high ... apiece. , Because they,re so inexpensive, the lenses ... tools to detect diseases in the field, scientific research ... education in classrooms. , "What I,m really excited ...
Breaking Biology News(10 mins):Treatment for deadly yeast disease reduced to 3 days 2Amazon rainforest survey could improve carbon offset schemes 2Bake your own droplet lens 2Bake your own droplet lens 3
... kills more people than breast, colorectal, pancreatic, and prostate ... the leading cause of mortality in intensive care units. ... fatal disease. Thanks to a generous grant of $138,238.65 ... Research Institute,s Dr. Michael Sharpe is exploring a new ...
... publication of new names in algae, fungi, and plants accepted ... paper that is being published simultaneously or will be published ... paper, co-authored by Sandra Knapp (London), John McNeill (Edinburgh) and ... articles to the Code and some ideas for ...
... No, this isn,t Jurassic Park. Researchers at the Johns Hopkins ... hunter in College Park, Md., have described the fossil of ... discovered, and a founder of a new genus and species ... Cretaceous Era. Nodosaurs have been found in diverse locations worldwide, ...
Cached Biology News:Could an apple a day keep sepsis away? 2Revolutionary changes to the Botanical Code published in 16 journals and 5 languages 2Newborn dinosaur discovered in Maryland 2
... The Multiple Species Tissue Array (MSTA) slides ... different cells and tissues from multiple species. ... on each MSTA slide which can then be ... staining, immunohistochemistry, or in situ hybridization. ...
... Medium (TSB), USP is a highly nutritious ... laboratory use. Due to the inclusion of ... will support growth of many fastidious organisms ... Product conforms to United States Pharmacopeia standards ...
... The Gene Pulser Xcell ... V, 50-60 Hz, is used ... This system includes the main ... (25-3,275 microfarad range) or square-wave ...
AVOID FREEZE/THAW CYCLES. Recognizes the ~5 kDa thymosin beta4 protein....
Biology Products: